"Natalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
| Descriptor ID |
D000069442
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.813 D12.776.124.790.651.114.224.060.813 D12.776.377.715.548.114.224.200.813
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Natalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Natalizumab [D12.776.124.486.485.114.224.060.813]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Natalizumab [D12.776.124.790.651.114.224.060.813]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Natalizumab [D12.776.377.715.548.114.224.200.813]
Below are MeSH descriptors whose meaning is more specific than "Natalizumab".
This graph shows the total number of publications written about "Natalizumab" by people in this website by year, and whether "Natalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 22 | 22 |
| 2006 | 0 | 21 | 21 |
| 2007 | 0 | 30 | 30 |
| 2008 | 0 | 32 | 32 |
| 2009 | 0 | 37 | 37 |
| 2010 | 0 | 56 | 56 |
| 2011 | 0 | 69 | 69 |
| 2012 | 0 | 64 | 64 |
| 2013 | 5 | 83 | 88 |
| 2014 | 14 | 94 | 108 |
| 2015 | 34 | 22 | 56 |
| 2016 | 63 | 22 | 85 |
| 2017 | 65 | 19 | 84 |
| 2018 | 31 | 18 | 49 |
| 2019 | 12 | 8 | 20 |
| 2020 | 4 | 6 | 10 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Natalizumab" by people in Profiles.
-
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. Ann Neurol. 2021 04; 89(4):780-789.
-
Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic. Mult Scler Relat Disord. 2021 Jan; 47:102642.
-
Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia. Mult Scler Relat Disord. 2020 Nov; 46:102516.
-
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care. Clin Neurol Neurosurg. 2020 10; 197:106203.
-
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? Mult Scler Relat Disord. 2020 Sep; 44:102250.
-
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations. Mult Scler Relat Disord. 2020 08; 43:102224.
-
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord. 2020 Aug; 43:102195.
-
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult Scler Relat Disord. 2020 Aug; 43:102174.
-
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2. J Neurol. 2020 05; 267(5):1567-1569.
-
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach. Mult Scler Relat Disord. 2020 Jun; 41:102165.